This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McGowan, E. M. Articles by Clarke, C. L. Search for Related Content PubMed PubMed Citation Articles by McGowan, E. M. Articles by Clarke, C. L.

Effect of Overexpression of Progesterone Receptor A on Endogenous Progestin-Sensitive Endpoints in Breast Cancer Cells

Westmead Institute for Cancer Research University of Sydney Westmead Hospital Westmead, New South Wales 2145, Australia

The human progesterone receptor (PR) is expressed as two isoforms, PRA and PRB, which differ in the N-terminal region and exhibit different activities in vitro, with PRA demonstrating dominant negative inhibitory effects on the activity of PRB and other nuclear receptors. PRA and PRB are expressed in target tissues at comparable levels although cells expressing a predominance of one isoform can be identified. In breast cancers, PRA is expressed at high levels in some tumors, and this may be associated with features of poorer prognosis. To investigate the role of PRA overexpression in PR-positive target cells, the effect of PRA induction on cell proliferation and expression of endogenous progestin-sensitive genes, SOX4 and fatty acid synthetase (FAS), was examined using PR-positive T-47D cell lines, which express a predominance of PRB, in which PRA could be increased 2- to 20-fold over basal levels. No effect of PRA induction was noted on cell proliferation, but marked changes in morphology, consistent with loss of adherent properties, were observed. Increases up to 4-fold in the relative PRA levels augmented progestin induction of SOX4 mRNA expression, and RU486 treatment revealed a progestin agonist effect. There was no consistent effect of PRA induction on progestin-mediated increases in FAS mRNA levels under these conditions. Clones with PRA:PRB ratios greater than 15 were associated with diminished progestin responses on both SOX4 and FAS mRNA expression. These data show that PRA overexpression is associated with alteration in adhesive properties in breast cancer cells and effects on endogenous progestin targets that were dependent on the cellular ratio of PRA:PRB. The results of this study are consistent with the view that PRA expression can fluctuate within a broad range in target cells without influencing the nature of progestin action on downstream targets, but that overexpression of PRA, such as is seen in a proportion of breast cancers, may be associated with inhibition of progestin action and features of poor prognosis.

This article has been cited by other articles:

				E. M. McGowan, A. J. Russell, V. Boonyaratanakornkit, D. N. Saunders, G. M. Lehrbach, C. M. Sergio, E. A. Musgrove, D. P. Edwards, and R. L. Sutherland Progestins Reinitiate Cell Cycle Progression in Antiestrogen-Arrested Breast Cancer Cells through the B-Isoform of Progesterone Receptor Cancer Res., September 15, 2007; 67(18): 8942 - 8951. [Abstract] [Full Text] [PDF]

				A. A. Merlino, T. N. Welsh, H. Tan, L. J. Yi, V. Cannon, B. M. Mercer, and S. Mesiano Nuclear Progesterone Receptors in the Human Pregnancy Myometrium: Evidence that Parturition Involves Functional Progesterone Withdrawal Mediated by Increased Expression of Progesterone Receptor-A J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1927 - 1933. [Abstract] [Full Text] [PDF]

				M. Aaboe, K. Birkenkamp-Demtroder, C. Wiuf, F. B. Sorensen, T. Thykjaer, G. Sauter, K. M.-E. Jensen, L. Dyrskjot, and T. Orntoft SOX4 Expression in Bladder Carcinoma: Clinical Aspects and In vitro Functional Characterization. Cancer Res., April 1, 2006; 66(7): 3434 - 3442. [Abstract] [Full Text] [PDF]

				A. H. Taylor, P. C. McParland, D. J. Taylor, and S. C. Bell The Progesterone Receptor in Human Term Amniochorion and Placenta Is Isoform C Endocrinology, February 1, 2006; 147(2): 687 - 693. [Abstract] [Full Text] [PDF]

				K. E. Boyd, Y.-Y. Xiao, K. Fan, A. Poholek, N. G. Copeland, N. A. Jenkins, and A. S. Perkins Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR Blood, January 15, 2006; 107(2): 733 - 741. [Abstract] [Full Text] [PDF]

				J. D. Graham, M. L. Yager, H. D. Hill, K. Byth, G. M. O'Neill, and C. L. Clarke Altered Progesterone Receptor Isoform Expression Remodels Progestin Responsiveness of Breast Cancer Cells Mol. Endocrinol., November 1, 2005; 19(11): 2713 - 2735. [Abstract] [Full Text] [PDF]

				M. J. Naylor, S. R. Oakes, M. Gardiner-Garden, J. Harris, K. Blazek, T. W. C. Ho, F. C. Li, D. Wynick, A. M. Walker, and C. J. Ormandy Transcriptional Changes Underlying the Secretory Activation Phase of Mammary Gland Development Mol. Endocrinol., July 1, 2005; 19(7): 1868 - 1883. [Abstract] [Full Text] [PDF]

				A L Ferry, D M Locasto, L B Meszaros, J C Bailey, M D Jonsen, K Brodsky, C J Hoon, A Gutierrez-Hartmann, and S E Diamond Pit-1{beta} reduces transcription and CREB-binding protein recruitment in a DNA context-dependent manner J. Endocrinol., April 1, 2005; 185(1): 173 - 185. [Abstract] [Full Text] [PDF]

				T. A. Hopp, H. L. Weiss, S. G. Hilsenbeck, Y. Cui, D. C. Allred, K. B. Horwitz, and S. A. W. Fuqua Breast Cancer Patients with Progesterone Receptor PR-A-Rich Tumors Have Poorer Disease-Free Survival Rates Clin. Cancer Res., April 15, 2004; 10(8): 2751 - 2760. [Abstract] [Full Text] [PDF]

				X.-L. Zhang, D. Zhang, F. J. Michel, J. L. Blum, F. A. Simmen, and R. C. M. Simmen Selective Interactions of Kruppel-like Factor 9/Basic Transcription Element-binding Protein with Progesterone Receptor Isoforms A and B Determine Transcriptional Activity of Progesterone-responsive Genes in Endometrial Epithelial Cells J. Biol. Chem., June 6, 2003; 278(24): 21474 - 21482. [Abstract] [Full Text] [PDF]

				B. M. Jacobsen, J. K. Richer, S. A. Schittone, and K. B. Horwitz New Human Breast Cancer Cells to Study Progesterone Receptor Isoform Ratio Effects and Ligand-independent Gene Regulation J. Biol. Chem., July 26, 2002; 277(31): 27793 - 27800. [Abstract] [Full Text] [PDF]

				J. K. Richer, B. M. Jacobsen, N. G. Manning, M. G. Abel, D. M. Wolf, and K. B. Horwitz Differential Gene Regulation by the Two Progesterone Receptor Isoforms in Human Breast Cancer Cells J. Biol. Chem., February 8, 2002; 277(7): 5209 - 5218. [Abstract] [Full Text] [PDF]

				D. Zhang, X.-L. Zhang, F. J. Michel, J. L. Blum, F. A. Simmen, and R. C. M. Simmen Direct Interaction of the Kruppel-like Family (KLF) Member, BTEB1, and PR Mediates Progesterone-Responsive Gene Expression in Endometrial Epithelial Cells Endocrinology, January 1, 2002; 143(1): 62 - 73. [Abstract] [Full Text] [PDF]

				R. L. Arnett-Mansfield, A. deFazio, G. V. Wain, R. C. Jaworski, K. Byth, P. A. Mote, and C. L. Clarke Relative Expression of Progesterone Receptors A and B in Endometrioid Cancers of the Endometrium Cancer Res., June 1, 2001; 61(11): 4576 - 4582. [Abstract] [Full Text] [PDF]

				J. Gao, J. Mazella, M. Tang, and L. Tseng Ligand-Activated Progesterone Receptor Isoform hPR-A Is a Stronger Transactivator Than hPR-B for the Expression of IGFBP-1 (Insulin-Like Growth Factor Binding Protein-1) in Human Endometrial Stromal Cells Mol. Endocrinol., December 1, 2000; 14(12): 1954 - 1961. [Abstract] [Full Text]